Especially from the immunological perspective, the complex interaction of tumor and microenvironment stands to gain significant insight from the use of high-throughput technology. In such studies, multiple tissue types comprising the tumor and its sorted and unsorted infiltrating lymphocyte populations can be stratified by prognostic effect to highlight biological markers with strong translational promise. A limiting factor for jointly immunologic and genomic investigations is the availability of statistical methods to parse evidence for tissue- specific interactions in signal transduction systems and tissue-specific effect modification. To this end, we have undertaken a genomic study involving tumor, tumor-infiltrating lymphocytes, and tumor-associated lymphocytes and we have developed the preliminary methods to identify functional and prognostic ligand- receptor signaling as well as immune-regulatory transcripts. The purpose of this grant is to further develop these methods and to apply them to our study data. Our primary motivation comes from collaborations with ovarian cancer immunologists who seek to use high-throughput gene expression data to hone immunotherapies: our conclusions will be directly relevant to improving the effect of cancer vaccines or removing barriers to their efficacy our methodological results will be applicable beyond this study and will enable future studies of an immunological and genomic nature. As a career development award, this proposal will provide Dr. Eng with the mentorship and protected time required to develop lines of statistical research with the eventual goal to seek the R01 funding required to establish an independent research program in ovarian cancer informatics.

Public Health Relevance

There is a significant need for informatics methods tailored to make inferences for the specialized mechanisms underlying the immunological response to cancer, a current and promising area of therapeutic research. This project investigates methods to identify and quantify evidence of immunological signaling and the multivariate effect of transcripts associated with immunological cell subtypes with the goal of producing a clear informatics workflow for hypothesis generation and validation. In addition, this project also provides a critical training opportunity for the candidate to develop immunological knowledge required for a successful career in combining cancer immunology, genomics and medical informatics and to develop as an independent R01 funded investigator.

Agency
National Institute of Health (NIH)
Institute
National Library of Medicine (NLM)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01LM012100-03
Application #
9251908
Study Section
Special Emphasis Panel (ZLM1-ZH-C (01)1)
Program Officer
Ye, Jane
Project Start
2015-04-01
Project End
2018-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
3
Fiscal Year
2017
Total Cost
$150,088
Indirect Cost
$11,117
Name
Roswell Park Cancer Institute Corp
Department
Type
Independent Hospitals
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Eng, Kevin H; Szender, J Brian; Etter, John Lewis et al. (2018) Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet 14:e1007194
Minlikeeva, Albina N; Freudenheim, Jo L; Eng, Kevin H et al. (2017) History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 26:1470-1473
Minlikeeva, Albina N; Freudenheim, Jo L; Cannioto, Rikki A et al. (2017) History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. Br J Cancer 117:1063-1069
Eng, Kevin H; Morrell, Kayla; Starbuck, Kristen et al. (2017) Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. Gynecol Oncol 146:52-57
Choi, J; Ye, S; Eng, K H et al. (2017) IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma Patients. Stat Biosci 9:1-12
Szender, J Brian; Papanicolau-Sengos, Antonios; Eng, Kevin H et al. (2017) NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 145:420-425
Surendran, Subin; Siddappa, Gangotri; Mohan, Amrutha et al. (2017) Cancer stem cell and its niche in malignant progression of oral potentially malignant disorders. Oral Oncol 75:140-147
Szender, J Brian; Emmons, Tiffany; Belliotti, Sarah et al. (2017) Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecol Oncol 146:491-497
Paluch, Benjamin E; Glenn, Sean T; Conroy, Jeffrey M et al. (2017) Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. Oncotarget 8:3197-3205

Showing the most recent 10 out of 31 publications